ASH Clinical News November 2016 | Page 55

TRAINING and EDUCATION You Make the Call Each month in “You Make the Call,” we’ll pick a challenging clinical question submitted through the Consult-a-Colleague program and post the expert’s response. But, what would YOU do? We’ll also pose a submitted question and ask you to send your responses. See how your answer matches up to the experts’ in the next print issue. This month, Allison King, MD, MPH, PhD, advises on how a patient with sickle cell disease (SCD) undergoing bariatric surgery should be managed. Clinical Dilemma: A 33-year-old female presents with SCD. Past hemoglobin electrophoresis shows double heterozygosity for Hb S and Hb C: HGB F 3.2 Hb S = 46.7% Hb C = 50.1%. Baseline hemoglobin is in the 10s. She has relatively mild disease clinically, with mild-mod pain crises once every one to two years, none in the last few years. The patient attributes this to having moved to Hawaii. (She experienced more pain crises previously, when she lived at elevation.) Her most recent significant hospitalization was in 2009 when she had pneumonia, Hb of 5 g/dL with fevers, HAs, and required 4-5U PRBCs. She has been transfused ~10 times in her lifetime. She is going to have bariatric surgery with a Roux en Y procedure. There are limited data published on how to manage these patients through such surgery, and we feel she should have exchange transfusion prior to surgery, though this is not available at our center or on the island of Hawaii. We do not have great experience with partial exchange. Please provide recommendations on how this patient should be managed. “Dr. King, thank you so much for your response. The only article regarding surgery in patients with SCD I could find was from 1998 (Neumayr L, et al. Surgery in patients with hemoglobin SC disease. Am J Hematol. 1998;57:101-8.). • Anemias • Hematopoietic cell transplantation • Hemoglobinopathies • Hemostasis/thrombosis • Lymphomas • Leukemias • Multiple myeloma & Waldenström macroglobulinemia Allison King, MD, MPH, PhD Associate Professor Medical Director, Survivorship Program for Siteman Cancer Center Program in Occupational Therapy Departments of Pediatrics and Medicine, Division of Hematology and Oncology Department of Surgery, Division of Public Health Sciences Washington University School of Medicine Washington University Saint Louis, MO Editor’s note: The doctor asking the question responded to Dr. King, asking for additional help over email. Here is that exchange: Consult a Colleague is a service for ASH members that helps facilitate the exchange of information between hematologists and their peers. ASH members can seek consultation on clinical cases from qualified experts in 11 categories: • Lymphoproliferative disorders Experts Make the Call Unless this patient has a history of stroke/acute chest/ asthma, I would not exchange the patient. If she does have stroke/acute chest/asthma, we would do a manual exchange: pull off 10 cc/kg and give back 5 cc/kg of packed red blood cells. If you would like our protocol for manual exchange, please let me know. Consult a Colleague Through ASH • Myeloproliferative disorders • Myelodysplastic syndromes • Thrombocytopenias Assigned volunteers (“colleagues”) will respond to inquiries within two business days (either by email or phone). It found that patients undergoing abdominal surgery had high rates of sickle cell crises if they were not transfused, but I recognize the study was small and the article is old. An article in UpToDate only included a small paragraph that recommends partial exchange in the pre-op setting to keep Hgb S <30 percent, so it’s not clear. We just don’t have a large population with this disorder.” Dr. King then shared a sickle cell order set, developed by the sickle cell team (comprising mostly nurses and nurse practitioners) at St. Louis Children’s Hospital – Washington University, with the doctor who asked the question. To view the order set, visit ashclinicalnews.org/category/ training-education/you-make-the-call. Have a puzzling clinical dilemma? Submit a question, and read more about Consult-a-Colleague volunteers at hematology.org/Clinicians/Consult.aspx or scan the QR code. *If you have a request related to a hematologic disorder not listed here, please email your recommendation to ashconsult@ hematology.org so it can be considered for addition in the future. DISCLAIMER: ASH does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this article is solely at your own risk. Next Month’s Clinical Dilemma: In 2012, I treated a young man with follicular lymphoma with four cycles of bendamustine/rituximab. He developed prolonged neutropenia (presumed ASHClinicalNews.org rituximab associated) that lasted eight months. He now has diffuse large B-cell lymphoma. Would you restart rituximab as part of a new chemotherapy regimen? Is he at higher risk for recurrence of rituximab-associated neutropenia? How would you respond? Email us at [email protected]. ASH Clinical News 53